 Connection
Samer Al Hadidi to Prognosis
This is a "connection" page, showing publications Samer Al Hadidi has written about Prognosis.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.386 |
|
|
|
-
Elemian S, Al Hadidi S. Targeting GPRC5D in multiple myeloma. Expert Rev Anticancer Ther. 2024 May; 24(5):229-238.
Score: 0.150
-
Al-Hadidi SA, Chuang HH, Miranda RN, Lee HJ. Programmed Cell Death-One Inhibition Therapy in Classical Hodgkin Lymphoma. Clin Lymphoma Myeloma Leuk. 2021 02; 21(2):e105-e111.
Score: 0.118
-
Schinke C, Rasche L, Ashby C, van Hemert R, Thanendrarajan S, Al Hadidi S, Zangari M, Bailey C, Alapat DV, Shaughnessy JD, Zhan F, Barlogie B, van Rhee F, Weinhold N. Prognostic impact of focal lesion location and persistence in multiple myeloma: insights from serial PET/DWI imaging. Blood Adv. 2025 Sep 09; 9(17):4368-4377.
Score: 0.041
-
Sun F, Cheng Y, Ma C, Xu H, Bailey C, Mery D, Ashby TC, Alapat D, Li Y, Young KH, Al Hadidi S, Thanendrarajan S, Schinke C, Zangari M, van Rhee F, Tricot G, Shaughnessy JD, Zhan F. Polyclonal plasma cell (PolyPC) signature as a key indicator for predicting the progression of MGUS to multiple myeloma. Cancer Biomark. 2025 Jun; 42(6):18758592251344936.
Score: 0.041
-
Mohan M, Gong Z, Ashby TC, Al Hadidi S, Thanendrarajan S, Schinke C, Alapat D, Shaughnessy JD, Zhan F, van Rhee F, Sawyer JR, Tian E, Zangari M. Concomitant deletion of the short arm (del(1p13.3)) and amplification or gain (1q21) of chromosome 1 by fluorescence in situ hybridization are associated with a poor clinical outcome in multiple myeloma. Cancer. 2023 08 15; 129(16):2491-2498.
Score: 0.035
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|